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LETTERS TO THE EDITOR
Elevated C-Reactive
Protein in Asymptomatic
Crohn’s Disease Patients:
Listen to the Sound of
Silence
To the Editor:
Bhattacharya et al1 confirmed and
extended their previous finding2 indicating
that “silent” Crohn’s disease (CD) patients
(i.e., asymptomatic patients with elevated
C-reactive protein [CRP] level) are a sub-
group of patients at the higher risk of hos-
pitalization and of more disabling disease.
We completely agree with the relevant role
of CRP in asymptomatic CD management,
and we conducted a cross-sectional obser-
vational study at our institution that
showed that such patients are at the higher
risk, even in the short time, of clinical flare.
In fact, from an electronic database
of prospectively collected data of patients
visited at the Inflammatory Bowel Disease
Outpatient Clinic of S. Andrea Hospital in
Rome, Italy, we evaluated a cohort of CD
patients at regular follow-up visit, from
January 2013 to December 2014. Inclu-
sion criteria were firm diagnosis of CD,
availability of clinical (age, sex, disease
location and duration, presence of extra-
intestinal manifestation, smoking status)
and biochemical (CRP, hemoglobin level)
data, Harvey–Bradshaw index # 4 (clin-
ical remission), and 1 year of recorded
follow-up from the index visit. From
a total of 97 CD patients with complete
data reports, 64 fulfilled inclusion criteria
for the study. Among those, 15 (23%) had
a CRP level at least 2-fold above the nor-
mal laboratory-reported value (“silent”
CD patients). Thirteen (20%) of 64 CD
patients in clinical remission experienced
a clinical flare of disease (empirically
defined by the onset of clinical symptoms
related to CD [abdominal pain and/or
diarrhea] that required a medical consulta-
tion). In that group, 6 patients (46%)
required steroids administration, and no
hospitalization was recorded. In a multi-
variate analysis, only elevated CRP value
showed independent association with dis-
ease flare onset at 1 year of follow-up
(P , 0.05). Patient with “silent” CD had
a significantly lower remission rate at 1
year compared with those with normal
CRP (60% versus 86%; log-rank test,
P , 0.05), with a 4-fold higher risk of
flare (odds ratio, 4; 95% confidence inter-
val, 1.0829–14.7754; P ¼ 0.038; Fig. 1).
In conclusion, despite the fact that
the relevance of CRP in the monitoring of
CD patients has been recognized from
a long time,3 CRP is not currently indicated
as a treatment target.4 Nonetheless, because
assessing bowel inflammation burden could
be challenging, we believe that the results
of the study of Bhattacharya et al, further
confirmed by the present retrospective
investigation, underline the important role
of CRP as a “surrogate”marker in CD man-
agement, even in the absence of clinical
symptoms. For the future, those findings
may open the door to the consideration of
specific treat-to-target trials to evaluate
possible influence on disease course of
treatment optimization aiming to normalize
CRP level in CD patients.
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Reply:
Thank you Dr Pagnini et al. for
your observations. Your letter to the
Editor confirms our findings regarding
silent Crohn’s disease—specifically that
patients who feel no symptoms have no
“early warning” mechanism to warn them
to seek care. The result is presenting with
FIGURE 1. Cumulative probability of remission rate at 1 year of follow-up (Kaplan–Meier curve)
in asymptomatic CD patients with normal or elevated CRP.
The authors have no conflict of interest to disclose.
Copyright © 2017 Crohn’s & Colitis Foundation of
America, Inc.
DOI 10.1097/MIB.0000000000001030
Published online 31 January 2017.
The author has no conflict of interest to disclose.
Copyright © 2017 Crohn’s & Colitis Foundation of
America, Inc.
DOI 10.1097/MIB.0000000000001037
Published online 31 January 2017.
Inflamm Bowel Dis  Volume 23, Number 3, March 2017 www.ibdjournal.org | E13
Copyright © 2017 Crohn’s & Colitis Foundation of America, Inc. Unauthorized reproduction of this article is prohibited.
